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Endemic Burkitt lymphoma (eBL), the most prevalent pediatric cancer in sub-Saharan 48 
Africa, is distinguished by its inclusion of Epstein-Barr virus (EBV). In order to better understand 49 
the impact of EBV variation in eBL tumorigenesis, we improved viral DNA enrichment methods 50 
and generated a total of 98 new EBV genomes from both eBL cases (N=58) and healthy 51 
controls (N=40) residing in the same geographic region in Kenya. Using our unbiased methods, 52 
we found that EBV type 1 was significantly more prevalent in eBL patients (74.5%) compared to 53 
healthy children (47.5%) (OR=3.24, 95% CI=1.36 - 7.71, P=0.007), as opposed to similar 54 
proportions in both groups. Controlling for EBV type, we also performed a genome-wide 55 
association study identifying 6 nonsynonymous variants in the genes EBNA1, EBNA2, BcLF1, 56 
and BARF1 that were enriched in eBL patients. Additionally, viruses isolated from plasma of 57 
eBL patients were identical to their tumor counterpart consistent with circulating viral DNA 58 
originating from the tumor. We also detected three intertypic recombinants carrying type 1 59 
EBNA2 and type 2 EBNA3 regions as well as one novel genome with a 20 kb deletion resulting 60 
in the loss of multiple lytic and virion genes. Comparing EBV types, viral genes displayed 61 
differential variation rates as type 1 appeared to be more divergent while type 2 demonstrated 62 
novel substructures. Overall, our findings highlight the complexities of EBV population structure 63 
and provide new insight into viral variation, potentially deepening our understanding of eBL 64 
oncogenesis. 65 
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● Improved viral enrichment methods conclusively demonstrate EBV type 1 as more 68 
prevalent in eBL patients compared to geographically matched healthy controls, which 69 
previously underrepresented the prevalence of EBV type 2. 70 
● Genome-wide association analysis between cases and controls identifies 6 eBL-71 
associated nonsynonymous variants in EBNA1, EBNA2, BcLF1, and BARF1 genes. 72 
● Analysis of population structure reveals that EBV type 2 exists as two genomic sub 73 
groups, and was more commonly found in females than male eBL patients.  74 
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EBV infects more than 90% of the world's population and typically persists as a chronic 76 
asymptomatic infection (1). While most individuals endure a lifelong infection with minimal 77 
effect, EBV is associated with ~1% of all human malignancies worldwide. EBV was first isolated 78 
from an endemic Burkitt lymphoma (eBL) tumor which is the most prevalent pediatric cancer in 79 
sub-Saharan Africa (2). Repeated Plasmodium falciparum infections during childhood appear to 80 
drive this increased incidence (3). Malaria causes polyclonal B-cell expansion and increased 81 
expression of activation-induced cytidine deaminase (AID) dependent DNA damage leading to 82 
the hallmark translocation of the MYC gene under control of the constitutively active 83 
immunoglobulin enhancer (4-6). How EBV potentiates eBL is incompletely understood, 84 
however, the clonal presence of this virus in almost every eBL tumor suggests a necessary role.  85 
EBV strains are categorized into two types based on the high degree of divergence in 86 
the EBNA2 and EBNA3 genes (7-9). This long standing evolutionary division is also present in 87 
orthologous primate viruses (10), yet remains unexplained. While EBV type 1 has been 88 
extensively studied (11, 12), because it causes acute infectious mononucleosis and other 89 
diseases in the developed world, type 2 virus studies have not kept pace since infected 90 
individuals are less frequent and found primarily in sub-Saharan Africa. This view is changing as 91 
several recent studies have reported a significant prevalence of type 2 circulating in western 92 
countries, suggesting a greater role for type 1 and greater potential for interactions between the 93 
EBV types worldwide (13, 14). For understanding endemic Burkitt, the African context provides 94 
a direct opportunity to examine viral variation because type 1 and type 2 are found in both eBL 95 
patients as well as healthy individuals (8, 15, 16). Viral variation has been shown to impact 96 
differential transformation and growth, and capacity to block apoptosis or immune recognition 97 
(7, 17, 18). However, studies focusing on only certain genomic regions/proteins potentially miss 98 
disease associations of other loci (19, 20). Although new studies have been conducted (21, 22), 99 
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genome-wide examinations in case-control studies are few and often lack typing the virus. A 100 
recent study which investigated whole EBV genomes for variant associations with 101 
nasopharyngeal carcinoma among Chinese patients has discovered two variants associated 102 
with increased disease risk (23). Similarly, another study investigated genome-wide variants of 103 
HIV genomes in quest of finding the associations with drug resistance (24). However, to the 104 
best of our knowledge, such viral genome-wide variant association for EBV and eBL remains to 105 
be explored. To address this shortfall and provide a proof of concept to the field, we sequenced 106 
a set EBV genomes in a disease/control setting. 107 
Whole genome sequencing of EBV is now attainable from tumor, blood, or saliva using 108 
targeted viral DNA capture methods (25-30). However, studying EBV from the blood of healthy 109 
individuals remains challenging due to low viral abundance relative to human DNA (1-10 EBV 110 
copy/ng blood DNA). In addition, EBV’s GC-rich genome is inefficiently amplified using 111 
conventional library preparation methods. Here, we present improved methods for EBV genome 112 
enrichment that allow us to sequence viruses directly from eBL patients and healthy children. 113 
Leveraging these samples, we sought to define the viral population structure and characterize 114 
viral subtypes collected from children hailing from the same region of western Kenya. 115 
Additionally, we performed the first genome wide association study to identify viral variants that 116 
correlate with eBL pathogenesis. 117 
Materials and Methods 118 
Ethical approval and sample collection 119 
For this study, we recruited children between 2009 and 2012 with suspected eBL, 120 
between 2-14 years of age, undergoing initial diagnosis at Jaramogi Oginga Odinga Teaching 121 
and Referral Hospital (JOOTRH; Kisumu), which is a regional referral hospital for pediatric 122 
cancer in western Kenya (31). We also enrolled healthy age-matched children residing in the 123 
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same malaria endemic regions of Kenya as controls. We obtained written informed consent 124 
from parents to enroll their child in this study. Ethical approval was obtained from the 125 
Institutional Review Board at the University of Massachusetts Medical School and the Scientific 126 
and Ethical Review Unit at the Kenya Medical Research Institute. From eBL patients, tumor 127 
biopsies were collected using fine needle aspirates (FNA) and transferred into RNAlater at the 128 
bedside, prior to induction of chemotherapy. From all children, peripheral blood samples were 129 
collected and fractionated by centrifugation prior to freezing into plasma and cell pellets. All 130 
samples were stored at -80°C prior to nucleic acid extraction.  131 
Cell cultures and controlled mixtures 132 
BL cultured cell lines, Namalwa, Daudi, Raji, and Jijoye were grown in a complete 133 
growth medium, RPMI 1640 (Life Technologies), with 2mM L-glutamine adjusted to contain 134 
1.5g/L sodium bicarbonate, 4.5g/L glucose, 10mM HEPES, 1.0mM sodium pyruvate, and 7.5% 135 
fetal bovine serum. We used Jijoye and Daudi as representative genomes of type 1 and type 2 136 
strains. For mixing experiments, we created relative ratios of Jijoye:Daudi of 10:90, 25:75, 137 
75:25, 90:10 in addition to sequencing each strain individually. 138 
Improved enrichment of GC-rich EBV in low abundance samples  139 
We used Allprep DNA/RNA/Protein mini kit (Qiagen) for DNA isolations from FNAs and 140 
QIAamp DNA Kit for blood and plasma. We developed an improved multi-step amplification and 141 
enrichment process for the GC-rich EBV genome, particularly in samples with low viral copies. 142 
We used EBV-specific whole genome amplification (sWGA) to provide sufficient material and 143 
targeted enrichment with hybridization probes after the library preparation. For this, we designed 144 
3’-protected oligos following the instructions from Leichty et al. (32). For low viral load samples, 145 
we added a multiplex long-range PCR amplification (mlrPCR) step, comprising two sets of non-146 
overlapping EBV-specific primers tiling across the genome (33). To increase viral DNA content 147 
in low abundant specimens, we applied an initial amplification with long range PCR using a 148 
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strategy consisting of two multiplexed sets of  primers which combined tiled the viral genome as 149 
designed by Kwok et al. To this, we added EBV type 2 specific primers. Following the initial 150 
multiplex long range (mlr) PCRs, we mixed two independent reactions and then performed 151 
specific whole genome amplification (sWGA) using phi29 polymerase with EBV-specific oligos. 152 
Overall DNA quality and quantities were assessed with NanoDrop and Picogreen and purified 153 
with 2x XP-Ampure magnetic beads. We prepared two reaction solutions with separate primer 154 
pools (2uL of 10uM each), using 2.5uL 10X long range PCR buffer Mg2+ (Qiagen), 1.25uL dNTP 155 
(10mM each), 0.15uL long range PCR enzyme mix (Qiagen), 5uL 5X Q-solution (Qiagen) to 156 
which we added 10ng of input DNA in 14 uL. The reaction conditions involved initial 157 
denaturation at 95°C for 3 min followed by 20 cycles  (95°C for 30 sec, gradient annealing 58°C 158 
to 49°C for 15 sec each, extension at 72°C for 7 min) and a final extension at 68°C for 10 min. 159 
We then mixed two independent reactions, denatured at 95°C for 3 min, and then added sWGA 160 
reaction buffer that contains 7uL 10X phi29 reaction buffer (NEB), 3uL dNTP mix (final 161 
concentrations: 30mM dGTP and dCTP; 10mM dATP and dTTP), 7uL EBV specific protected 162 
oligo Mix (10uM each), 2uL phi29 polymerase (10U/uL, NEB), 0.7uL BSA (0.1ug/uL), and 0.3uL 163 
H2O. For samples with higher viral loads that did not require PCR amplification prior to sWGA, 164 
we denatured DNA using the same conditions but replaced the reaction buffer with TE or TE-Q-165 
solution mix. We incubated the sWGA at 30°C for 16h followed by incubation at 65°C for 15 min 166 
to stop the reaction. Instead of random hexamers for MDA (multiple strand displacement 167 
amplification) reaction, we used EBV specific hexamers with 3’-end modification to protect 168 
against phi29 exonuclease activity (see supplementary document for primer sequences). For 169 
WGA with Genomiphi v2 kit, we followed the manufacturer’s instructions modified by adding 170 
extra 2x dGTP and dCTP. For hybrid capture, we followed MyBait protocol as manufacturer’s 171 
recommendations. Following incubation at 65°C for 72 hours, we purified hybridization products 172 
with streptavidin beads and used Kapa HiFi to amplify the captured library. We quantified viral 173 
content with bi-plex qPCR using primers for viral BALF5 and human beta-actin gene (34). For 174 
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validation of EBV subtypes, we used primers spanning EBNA3C gene producing 153bp and 175 
246bp products for type 1 and type 2, respectively (see Supplemental Table 1 for all primers). 176 
We improved the amplification yield by adding extra 2x dGTP/dCTP to the amplification 177 
buffers, especially for low EBV inputs (10 EBV copy/uL) (Table 1). We also tested the effect of 178 
Q-solution (Qiagen) on sWGA yield and found that EBV yields were almost doubled (Figure 1A 179 
and 1B). In addition, we found that prolonged sWGA incubation time (16 hours) improved 180 
amplification yield compared with relatively shorter time (8 hours). Combining the above 181 
methods allowed for adequate input for hybrid capture even from low viral load healthy controls. 182 
Sequence design for RNA baits 183 
Capture bait sequences were designed using in-house scripts to target both type 1 and 184 
type 2. In addition to type 1 and type 2 references, we also designed against other available 185 
complete genomes including Mutu I, Akata, GD1 and GD2 to ensure the capture of divergent 186 
regions. Specifically, the design consisted of overlapping 120nt probes tiling every 30 bases 187 
(4x overlapping tiling) across the genomic sequences with increased probes for regions with 188 
elevated GC content (>65%). Additional probes were added based on the sequential analysis 189 
of additional genomes, when current probes were greater than 5% divergent or there was a 190 
gap in coverage for a specific region (Supplemental Table 2).  191 
Sequencing library preparation and hybrid capture enrichment 192 
Illumina sequencing library preparation steps consisted of DNA shearing, blunt-end 193 
repair (Quick Blunting kit, NEB), 3'-adenylation (Klenow Fragment 3' to 5' exo-, NEB), and 194 
ligation of indexed sequencing adaptors (Quick Ligation kit, NEB). We PCR amplified libraries to 195 
a final concentration with 10 cycles using KAPA HiFi HotStart ReadyMix and quantified them 196 
using bioanalyzer. We then pooled sample libraries balancing them according to their EBV 197 
content and proceeded to target enrichment hybridization using custom EBV-specific 198 
biotinylated RNA probes (MyBaits, Arbor Biosciences). We performed sequencing using  199 
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Illumina MiSeq, HiSeq 2000, and NextSeq 500 platforms with 1x75bp, 2x100bp, and 2x150bp, 200 
respectively. 201 
Sequence preprocessing and de novo genome assembly 202 
We checked the sequence quality using FastQC (v0.10.1) after trimming residual 203 
adapter and low quality bases (<20) using cutadapt (v1.7.1) (35) and prinseq (v0.20.4) (36), 204 
respectively. After removing reads that mapped to the human genome (hg38), we de novo 205 
assembled the remaining reads into contigs with VelvetOptimiser (v2.2.5) ⁠(37) using a kmer 206 
search ranging from 21 to 149 to maximize N50. We then ordered and oriented the contigs 207 
guided by the reference genomes (NC_007605.1 for type 1 and NC_009334.1 for type 2)  using 208 
ABACAS, extended with read support using IMAGE (38) ⁠, and merged the overlapping contigs to 209 
form larger scaffolds (using in-house scripts). By aligning reads back to scaffolds, we assessed 210 
contig quality requiring support from ≥5 unique reads. We created a final genome by 211 
demarcating repetitive and missing regions due to low coverage with sequential ambiguous “N” 212 
nucleotides. We excluded minor variants (<5% of reads) in final assemblies.  213 
Diversity and variant association analysis 214 
We used Mafft (v7.215) (39) to generate multiple sequence alignment (msa) of 215 
genomes, and masked the repetitive regions predefined in EBV reference genome, 216 
NC_007605, in addition to repeat regions larger than 100nt detected by miropeat (40). For 217 
analyses based on viral genes, we extracted the coding region sequences from msa of 218 
assemblies according to the reference genome Genbank annotations. The substitutions in 219 
coding regions were translated in protein sequences based on standard genetic code. The 220 
genetic distance between the sequences were calculated using Kimura-2-parameter method 221 
based on transition and transversion frequencies.  We calculated dN/dS rates per gene based 222 
on pairwise Nei-Gojobori algorithm using the python functions provided by 223 
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https://github.com/a1ultima/hpcleap_dnds/ after excluding frameshift insertions and ambiguous 224 
bases. We constructed whole genome phylogenetic trees based on neighbor-joining method 225 
and protein sequence trees based on maximum likelihood method with Jukes-Cantor 226 
substitution model using MEGA (v6.0) (41). We determined variant sites of each isolate in 227 
reference to the EBV reference genome, NC_007605, based on msa using snp-sites (v2.3.2) 228 
(42). For principal coordinate analysis (PCoA), we used R package dartR (v1.0.5) (43). We 229 
performed the variant association analysis using the ‘v-assoc’ function from PSEQ/PLINK (44). 230 
To control for multiple testing, we calculated empirical p-values with one million permutations 231 
(pseq proj v-assoc --phenotype eBL --fix-null --perm 1000000) with EBV type stratification which 232 
permutes within types (--strata EBVtype). 233 
Deposited genomes can be accessed from European Nucleotide Archive (ENA) 234 
database with accession PRJEB38735 (study accession: ERP122181) and raw reads can be 235 
downloaded from Sequence Read Archive (SRA) database with Bio-project accession number 236 
PRJNA552587 (study accession: SRP212943). 237 
 238 
Results 239 
Study participant characteristics 240 
The objective of this study was to examine EBV genetic variation in a region of western 241 
Kenya with a high incidence of eBL (31) and determine if any variants are associated with eBL 242 
pathogenesis. We leveraged specimens from eBL patients and healthy children residing in the 243 
same geographic area (Figure 1C) (31). We sequenced the virus isolated from 58 eBL cases 244 
and 40 healthy Kenyan children, as controls. Patients between 1 and 13 years of age were 245 
predominantly male (74%), consistent with the sex ratio of eBL (Table 2) (31). Healthy controls 246 
had similar levels of malaria exposure based on previous epidemiologic studies (45). Control 247 
samples ranged in age from 1 to 6 years. This difference in age was necessarily due to the 248 
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finding that younger, healthy yet malaria-exposed children have higher average viral loads 249 
compared to older children who have developed immune control over this chronic viral infection 250 
(34). Therefore, it was infeasible to age-match controls with the eBL cases who tend to be older. 251 
We make the assumption that children are infected with the same herpes virus throughout life 252 
and therefore genomes from younger children reflect EBV genomes that would be found in older 253 
children.  254 
Sequencing and assembly quality 255 
EBV is a large GC-rich double stranded DNA virus with a 172 kb genome of which ~20% 256 
is a repetitive sequence. For the majority of eBL patients, we prepared sequencing libraries 257 
directly from tumor DNA followed by hybrid capture enrichment. For low copy viral samples, 258 
such as eBL plasma and healthy control blood, we designed and implemented additional viral 259 
whole genome amplification and enrichment prior to library preparation and sequencing (Figure 260 
1C). We generated a study set of 114 genomes including replicates from cell lines and primary 261 
clinical samples, representing 98 cases and controls. In addition, we sequenced 20 technical 262 
replicates for quality control purposes such as estimation of re-sequencing error or sWGA bias, 263 
and sensitivity of detection of mixed infections. The baseline re-sequencing error rate was 264 
limited to ~1.1x10-5 bases when our assemblies are compared with high-quality known strain 265 
genomes (46) (Table 3). The mean error rate was ~2.1x10-5 bases for sWGA with GenomiPhi, 266 
while it is ~1.1x10-4 bases when we used more sensitive mlrPCR-sWGA (Methods). We 267 
obtained an average of ~5 million reads, resulting in an average 9,688 depth of coverage across 268 
assemblies (Supplemental Table 3). De novo sequence assembly created large scaffolds 269 
covering non-repetitive regions, except three isolates with low coverage, yielded a median of 270 
137,887bp genomes (ranging 47,534bp - 146,920bp). We determined the types of each isolate 271 
by calculating the nucleotide distance to both reference types in addition to read mapping rates 272 
against type-specific regions. Despite our ability to experimentally detect mixed types at levels 273 
 on D
ecem























as low as 10% (Figure 2A), we found no evidence of mixed infections in our cases and controls. 274 
Also, to ensure that our sample inclusion was unbiased when selecting healthy individuals with 275 
high enough viremias to sequence, we quantified the baseline viral loads with bi-plex qPCR 276 
using primers for viral BALF5 and human beta-actin gene (see Supplemental methods). We 277 
compared the viral loads and found no significant difference between type 1 and 2 (P=0.529, 278 
Figure 2B).  279 
Equivalence of tumor and plasma viral DNA in eBL cases 280 
Plasma EBV load has been studied to show its potential as a biomarker or as a 281 
prognostic marker in various lymphomas including BL (47, 48). We included plasma specimens 282 
along with the tumor biopsies from eBL patients in the whole genome sequencing set to 283 
compare and contrast the two counterparts at the sequence level. Following the separate 284 
sequencing and genome assembly of 6 pairs of plasma and tumor associated viruses from 6 285 
patients, we confirmed that viral DNA in the plasma was representative of the virus in the tumor 286 
cells (Figure 2C). Accounting for the sequencing errors, the pairs appeared to be identical 287 
(Supplemental Figure 1). Out of these pairs, we further confirmed the subtype of three EBV 288 
isolates (eBL-Tumor-0035, -0037, and -0038) from the plasma and tumor biopsies using type-289 
specific PCRs (see Supplemental method) in addition to 5 other samples (eBL-Tumor-0003, -290 
0019, -0022, -0029, and -0030). Overall, these findings demonstrate that viral DNA isolated 291 
from eBL patient plasma represents the tumor virus and reflects its genome sequence to the 292 
circulating system. This further assures the potential of plasma DNA for prognostic tools in 293 
disease monitoring. 294 
Structural variation and intertypic recombinants 295 
First, we looked for large deletions within our viral genomes, but did not detect any of the 296 
previously described deletions in EBNAs, even though we were able to detect, as positive 297 
controls, EBNA3C deletion in Raji and the EBNA2 deletion in Daudi cell lines. However, in one 298 
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sample we did detect a novel 20kb deletion, spanning from 100 kb to 120 kb in the genome 299 
(Figure 2D), which appears as the lack of sequencing read coverage while the rest of the 300 
genome, even high GC regions, show high sequencing depth (> 6,000x in average). This 301 
deleted region normally encodes multiple lytic phase genes, e.g. BBRF1/2, BBLF1/3, 302 
BGLF1/2/3/4/5, and BDLF2/3/4. Interestingly, none of the latent genes were affected by this 303 
deletion.  304 
Next, we interrogated our isolates by comparing the pairwise similarities of each genome 305 
against EBV type 1 and type 2 references. By traversing through the genome with a window, we 306 
were able to delineate regions that were more similar to one type over the other (Figure 2E). As 307 
expected, Jijoye, a type 2 strain, displayed less similarity against type 1 reference around its 308 
EBNA2 and EBNA3 genes, the most divergent region between types, while Namalwa as a type 309 
1 strain shows the same pattern of dissimilarity against type 2 reference around the same 310 
regions. Interestingly, we found three patient-derived genomes, eBL-Tumor-0012, eBL-Tumor-311 
0033, and eBL-Plasma-0049, with mixed similarity trends. Similar to a previously detected 312 
recombinant strain (LN827563.2_sLCL-1.18) (46), all of the intertypic isolates carried type 1 313 
EBNA2 and type 2 EBNA3 genes. Although these new intertypic hybrids were all isolated from 314 
eBL patients only as opposed to healthy controls, this finding does not reach to a statistical 315 
significance (P=0.268, Chi-square). 316 
Genomic population structure is driven by type differences with distinct substructure in 317 
type 2 viruses.  318 
Our samples present a unique opportunity to study population structure of EBV types 319 
and their co-evolution within a geographically defined region. As expected, the major bifurcation 320 
within the phylogenetic tree based on the entire genome occurs between type 1 and type 2 321 
viruses (Figure 3A). Viruses from eBL patients as well as healthy controls appeared to be 322 
intermixed almost randomly within the type 1 branch. Interestingly, within type 2 genomes 8 323 
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eBL-associated isolates formed a unique sub-cluster. The hybrid genomes are clustered with 324 
type 2s, which is consistent with type 2 EBNA3s representing a greater amount of sequence 325 
than the type 1 EBNA2 region. 326 
We further explored viral population structure with principal coordinate analysis (PCoA) 327 
of variation across the genome. While the first three components cumulatively explain 57.2% of 328 
the total variance, the first component, which solely accounted for 43.9% of the variance, 329 
separates genomes based on type 1 and type 2 (Figure 3B, upper plot). Similar to the 330 
phylogenetic tree, intertypic genomes are positioned more closely to type 2s. Interestingly, the 331 
second and predominantly third components separate type 2 viruses into two distinct clusters, 332 
group A and B (Figure 3B, lower plot). These clusters were reflected, although not as 333 
distinctly, in the structure of the phylogenetic tree in the Figure 3A as well. The PCoA loading 334 
values, which accounts for 37.1% of the variance between the type 2 groups, are predominantly 335 
driven by correlated variation spanning 70kb upstream of EBNA3C (Figure 3C and D). 336 
Together these findings suggest that there are two EBV type 2 strains circulating within this 337 
population. We also examined viral variation from the perspective of LMP1. Interestingly, the 338 
vast majority of viruses were grouped into Alaskan and Mediterranean strains (Supplemental 339 
Figure 2). The majority of genomes that carry Alaskan LMP1 are type 2 genomes, while 340 
Mediterranean strain LMP1s are mostly from type 1 genomes. For all available LMP1 type 2 341 
sequences, group A and group B correlated with Mediterranean and Alaskan, respectively. 342 
EBV type 2 has less diversity compared with type 1 343 
We further explored the pattern and nature of genomic variation across the genome 344 
comparing and contrasting EBV type 1 and type 2. Examining the pairwise divergence of coding 345 
genes for all viral genomes, we found that the divergence was the highest in the type-specific 346 
EBNA genes (EBNA2 and EBNA3s), in particular, with EBNA2 showing the greatest divergence 347 
(d=0.1313 ± 2.3x10-3) (Figure 4A, upper panel). Investigating each type separately, the 348 
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diversity within types was low for EBNA2 and EBNA3Cs, consistent with type 1 and 2 being 349 
separated by many fixed differences (Figure 4A, middle panel). In both types, intra-type 350 
divergence was greatest for EBNA1 and LMP1. Most remarkable was the fact that type 2 351 
generally showed lower levels of divergence across the genome (0.0047 ± 3.7x10-3 and 0.0025 352 
± 2.7x10-3 for type 1 and type 2, respectively). We observed the same trend even with the 353 
balanced sample sizes through random down-sampling (Supplemental Figure 3A and B). 354 
Overall, these measures suggest that EBV gene evolutionary rates differ by types. 355 
To explore signatures of evolutionary selection, we examined the dN/dS ratios within 356 
coding sequences (Figure 4A, lower panel). Overall most genes showed signals of purifying 357 
selection, as indicated by ω < 1.0, except LMP1, BARF0, and BKRF2 (only type 2). 358 
Interestingly, with dN/dS measures, EBNA2, BSLF1, BSLF2, and BLLF2 genes had relatively 359 
higher rates in type 2 compared to type 1 (P < 0.001). Having significantly different ω values for 360 
multiple genes (P < 0.001, t-test) can suggest the existence of differential evolutionary pressure 361 
on these two divergent types. This can be interpreted as an ongoing adaptation process of type 362 
2 genomes (through certain genes) in the population while fixed functions of these genes for the 363 
type 1 genomes. Overall, the magnitude of average nonsynonymous and synonymous changes 364 
per gene, normalized by gene length, reflect the high-level diversity accumulated in certain 365 
genes (Supplemental Figure 4). Latency-associated genes generally have the highest non-366 
synonymous variant rates, but they also have the highest synonymous rates consistent with 367 
longstanding divergence (Figure 4B). Other functional categories, including lytic genes, have 368 
relatively low levels of nonsynonymous mutations suggesting stronger purifying selection (see 369 
Supplemental Table 4 for functional categories).  370 
Global context of Kenyan viruses 371 
To more broadly contextualize our viral population from western Kenya, we examined 372 
the phylogeny of the Kenyan viruses along with other publicly available genomes from across 373 
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the world (Supplemental Table 5). Among all isolates, the most polymorphic genomic regions 374 
appeared to be around EBNA2 and EBNA3 genes (Supplemental Figure 5A). Phylogenetic 375 
tree shows that the major types, type 1 and type 2, are the main demarcation point regardless of 376 
the source or geographic location. The three intertypic genomes from our sample set neatly 377 
cluster with the previously isolated intertypic hybrid, sLCL-1.18 (Supplemental Figure 5B). 378 
Type 1 genomes from our study were split into two groups, with one forming a sub-branch only 379 
with Kenyan type 1, including Mutu, Daudi, and several Kenyan LCLs. The second group 380 
interspersed with other African (Ghana, Nigeria, North Africa) and non-African isolates. In 381 
addition, a few of our genomes from healthy carriers clustered with a group of mainly Australian 382 
isolates, however; none of them clustered with the South Asian group. Our Kenyan EBV type 2s 383 
generally intermixed with other type 2 genomes.  384 
Viral Genomic Variants and Associations with eBL 385 
Previous studies, which examined viral sequence variants with relative frequencies, 386 
often lack properly controlled disease association analysis in genome-wide context (14, 49). 387 
After excluding the intertypic hybrids, we compared type frequencies of EBV genomes isolated 388 
from eBL patients and healthy controls. We observed a significant difference in frequencies with 389 
74.5% of eBLs carrying type 1 while only 25.5% carried type 2 infections. In contrast, 47.5% vs. 390 
52.5% of type 1 and type 2, respectively were found in healthy controls. EBV type 1 was 391 
associated with eBL (OR=3.24, 95% CI=1.36 - 7.71, P = 0.007, Fisher’s exact) (Figure 4C), 392 
independent of age and gender (all P>0.05, Supplemental Figure 6). The type 1 prevalence 393 
was still ~70% (and 30% type 2) among eBL children who are within the equivalent age range of 394 
their healthy counter-parts (1-6 years old). The breakdown of the subtype frequencies based on 395 
gender revealed that the female eBL patients most frequently carried type 2 (type 1 N=14 vs 396 
type 2 N=2) while their healthy counterparts showed the opposite trend (type 1 N=7 vs type 2 397 
N=26) (Table 4). On the other hand, male individuals carried both subtypes with roughly 398 
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equivalent frequencies regardless of their disease status (N=27 vs N=26 and N=12 vs N=16, 399 
type 1 and type 2 among eBL and healthy control groups, respectively). We then expanded the 400 
association analysis to all 6191 synonymous and non-synonymous single nucleotide variations 401 
across the entire genome (Figure 4D and Supplemental Table 6). We conducted an initial 402 
association test for each nonsynonymous variant and detected 133 significant associations 403 
(Supplemental Table 7 and Methods). The vast majority of these variants were located within 404 
the type1-type2 region given the highly correlated nature of this region (Supplemental Figure 405 
7). We then stratified by type to detect variants independent of viral type. This yielded 6 variants 406 
solely associated with the disease (Table 5). Variant 37668T>C represents a serine residue 407 
change to a proline at the C-terminus of EBNA2 (S485P) which is carried by 24/54 eBL cases; 408 
while this variant was present in only 2/36 healthy controls. Two variants in EBNA1 at 409 
95773A>T and 95778T>G (N38Y and H39Q, respectively) were both observed in 3/57 eBL 410 
isolates while their corresponding frequencies were 11/36 and 12/37 among healthy controls. 411 
These two variants fall into one of the two chromosome binding domains of the EBNA1 protein 412 
which plays a bridging role for tethering the viral episome to the host chromosome (50, 51). 413 
Other two significant variants we detected are within the BcLF1 gene which encodes for viral 414 
major capsid protein. This protein is the most essential component of the self-assembly 415 
structures for the viral capsid (52). Elevated substitution rates in viruses of healthy controls as 416 
opposed to eBL associated viruses comply with their role in capsid formation and pathogenesis. 417 
The BARF1 variant with higher frequencies in eBL associated viruses that replaces the valine 418 
residue with an alanine might provide a fitness advantage with its role as a soluble form of CSF-419 
1 receptor that neutralizes effects of human CSF-1. With this residual change in the protein, 420 
BARF1 increases its sequence identity to human CD80 as both share the same amino acid, 421 
alanine, at the position 29 (53).  422 
Nucleotide variants in non-coding and promoter regions can affect regulation of viral 423 
gene expression and activity within host cells. BZLF1 is a regulator gene of lytic reactivation and 424 
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classified based on its promoter as prototype Zp-P (B95-8) and Zp-V3 (M81 strain). Zp-V3 425 
variant of the promoter has recently been found to enhance lytic activity and over-represented in 426 
EBV-positive BLs (54). Therefore, we sought to find out whether our dataset can validate the 427 
association. We determined variants at seven positions in the upstream promoter region of 428 
BZLF1 (Supplemental Table 8). Interestingly, all of the Kenyan viruses carried C at positions 429 
both -525 and -274 (as in Zp-P) regardless of promoter type. We also found that -532 and -524 430 
are variable in our isolates while these two are not variant in both promoter types. Our results 431 
show that only 12.5% (5/40) type 1 promoter sequences fully resembled Zp-V3 in eBL group as 432 
opposed to 22% (2/9) healthy genomes, while all of the type 2 genomes, without exception, 433 
carried Zp-V3 type promoter regardless of disease status.  434 
Discussion 435 
In this study, we investigated genomic diversity of EBV by sampling viruses from 436 
children in western Kenya where eBL incidence is high (45). Our improved methods allowed us 437 
to sequence asymptomatically infected healthy controls with relatively low peripheral blood viral 438 
loads, and thereby examine the virus in the population at large (34). We performed the first 439 
association study comparing viral genomes from eBL patients and geographically matched 440 
controls, without the need for viral propagation in LCLs; thus showing that type 1 EBV, as well 441 
as potentially several non-type specific variants, are associated with eBL. Furthermore, as the 442 
first study that characterized significant numbers of EBV type 2, we were able to compare and 443 
contrast both types and explore the viral population, thus discovering novel differences including 444 
population substructure and in female to male frequencies in EBV type 2. An extended cohort is 445 
required to further validate our results. 446 
Our sequencing data demonstrated that EBV from plasma is representative of the tumor 447 
virus in eBL patients. This is consistent with the premise that peripheral EBV DNA originates 448 
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from apoptotic tumor cells given that cell-free EBV DNA in eBL patients are mostly unprotected 449 
against DNase (55), as opposed to being encapsidated during lytic reactivation, and that plasma 450 
EBV levels are associated with tumor burden and stage (48). These findings support the use of 451 
plasma viremia as a surrogate biomarker for tumor burden and the development of plasma-452 
based prognostic tests with predictive models that could be used during clinical trials (48). The 453 
lack of mixed infections observed in our healthy controls could be due to the limit of detection in 454 
blood compared to viruses isolated from saliva (14). Further studies are needed to extrapolate 455 
and understand the coevolution and dynamics of both EBV types. 456 
In addition, we detected three intertypic recombinant EBV genomes solely found within 457 
our eBL patients; similar to those previously described in other cancers (56). It is unclear 458 
whether the intertypic genomes represent a common event with subsequent mutation and 459 
recombination or multiple independent events. If the latter is true, it supports more frequent 460 
mixed-type infections given that both parents have to be present in the same cell (57-59). It is 461 
interesting that all four intertypics observed to date carry the same type EBNA2/EBNA3 462 
combinations with the type 2 genes being so closely related (Supplemental Figure 8). Thus, if 463 
multiple events have generated these viruses, it suggests that certain strains may have a 464 
greater proclivity to recombine. Further studies will be needed to better define the intertypic 465 
population, their origins and their association with disease.  466 
Importantly, we were able to explore EBV population genetics and compare and contrast 467 
type 1 and type 2 because of their co-prevalence in Africa. As well described, the major 468 
differentiation in terms of genetic variability was the variation correlated with type 1 and type 2 469 
viruses. These viral types showed distinct population characteristics with type 1 harboring 470 
greater diversity especially in functionally important latent genes. Combined with the observed 471 
nucleotide diversity, latency genes appear to have long standing divergence that has 472 
accumulated significant synonymous changes (as opposed to recent sweeps on 473 
nonsynonymous changes that would erase synonymous variants). Global phylogenetic analysis 474 
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emphasizes this diversity by providing two main subgroups for type 1 genomes in our 475 
sequencing set. One group represents core local Kenyan viruses while the second group is a 476 
mixture of viruses from across the globe, with the exception of South Asian viruses that group 477 
apart. While previously sequenced type 2 viruses intermingle with western Kenya isolates, the 478 
majority of these originated from East Africa with only a few from West Africa. Interestingly, 479 
intermingling is also true for type 2 as we observed two distinct groups. This is more apparent in 480 
PCA where type 2 virus forms 2 clusters. Examination via PCA, the loading values are 481 
determined by a broad stretch of the genome from the end of EBNA3C to LMP1, where 482 
Mediterranean and Alaskan designations correlate. It remains to be determined whether this 483 
substructure might be due to the introduction of previously geographically isolated viruses or 484 
distinct evolutionary trajectories within the population. Further study is needed with broader 485 
samplings to understand its significance but our findings suggest that there may be significant 486 
epistasis potentially including LMP1.  487 
By sequencing the virus directly from healthy controls, we were able to address the 488 
question of relative tumorigenicity between EBV type 1 and 2. We evaluated the long-standing 489 
presumption that type 1 virus is more strongly associated with eBL, in contrast to type 2. Our 490 
work was able to more definitely answer this question as we were not reliant on LCLs from 491 
healthy controls where type 1 bias in transformation might explain the lack of previous 492 
associations. We earlier demonstrated, by mutational profiling of EBV positive and negative eBL 493 
tumors, that the virus, especially type 1, might mitigate the necessity of certain driver mutations in 494 
the host genome (16). In addition, our genome-wide results controlling for viral type substantiates 495 
investigations of non-type associated variation that could also impart oncogenic risk, as we 496 
found suggestive trends for several nonsynonymous variants as well. Supporting the putative 497 
existence of EBV sub-strains that have increased oncogenic potential, we observed sub-cliques 498 
of solely eBL or control isolates within the type 2 genomes. Although these sub-groups were 499 
formed with only 7 or 8 members, the significance of this observation will be deciphered with 500 
 on D
ecem























more extensive cohorts. On the other hand, only a small subset of type 1 viruses from eBL 501 
patients carried BZLF1 promoter variant, which leads to a gain of function (54), while all type 2 502 
viruses carried this variant suggesting this promoter might be beneficial for type 2 but makes it 503 
unlikely to be a driver of oncogenesis. It is essential to remind that the suggestive associations 504 
we uncovered are in need of further validation with independent cohorts and treated cautiously. 505 
Overall, our population-based study provides the groundwork to unravel the complexities 506 
of EBV genome structure and insight into viral variation that influences oncogenesis. Genomic 507 
and mutational analysis of BL tumors identified key differences based on viral content 508 
suggesting new avenues for the development of prognostic molecular biomarkers and the 509 
potential for antiviral therapeutic interventions.  510 
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10,000 TE 62,448 3,456 30/30/10/10 16 hours at 30C 4,573 7 1.06 0.03 35.33 
1,000 TE 10,038 13,911 30/30/10/10 16 hours at 30C 505 59 1.01 0.08 12.63 
100 TE 467 10,883 30/30/10/10 16 hours at 30C 55 70 2.28 0.12 19.00 
10 TE 10 11,326 30/30/10/10 16 hours at 30C 4 68 8.26 0.12 68.83 
1 TE 6 19,483 30/30/10/10 16 hours at 30C 0 55 0.21 0.06 3.50 
0 TE 
 





10,000 TE 62,448 3,456 30/30/5/5 16 hours at 30C 4,847 2 1.12 0.01 112.00 
1,000 TE 10,038 13,911 30/30/5/5 16 hours at 30C 544 75 1.09 0.11 9.91 
100 TE 467 10,883 30/30/5/5 16 hours at 30C 72 65 3 0.12 25.00 
10 TE 10 11,326 30/30/5/5 16 hours at 30C 3 65 5.97 0.11 54.27 
1 TE 6 19,483 30/30/5/5 16 hours at 30C 0 81 0.22 0.09 2.44 
0 TE 
 





10,000 TE 62,448 3,456 15/15/5/5 16 hours at 30C 3,483 16 0.81 0.07 11.57 
1,000 TE 10,038 13,911 15/15/5/5 16 hours at 30C 488 84 0.97 0.12 8.08 
100 TE 467 10,883 15/15/5/5 16 hours at 30C 73 109 3.04 0.19 16.00 
10 TE 10 11,326 15/15/5/5 16 hours at 30C 1 80 2.71 0.14 19.36 
1 TE 6 19,483 15/15/5/5 16 hours at 30C 0 103 0.25 0.11 2.27 
0 TE 
 





10,000 TE 62,448 3,456 15/15/2/2 16 hours at 30C 3,324 12 0.77 0.05 15.40 
1,000 TE 10,038 13,911 15/15/2/2 16 hours at 30C 533 77 1.06 0.11 9.64 
100 TE 467 10,883 15/15/2/2 16 hours at 30C 78 105 3.24 0.19 17.05 
10 TE 10 11,326 15/15/2/2 16 hours at 30C 4 105 7.8 0.18 43.33 
1 TE 6 19,483 15/15/2/2 16 hours at 30C 0 110 0 0.12 0.00 
0 TE 
 










10 TE 10 11,326 30/30/5/5 8 hours at 30C 2 40 6.31 0.14 45.07 
10 TE 10 11,326 30/30/5/5 16 hours at 30C 2 40 8.74 0.14 62.43 
10 TE 10 11,326 30/30/5/5 8 hours at 35C 1 22 4.05 0.08 50.63 
10 TE 10 11,326 30/30/5/5 16 hours at 35C 2 22 6.14 0.08 76.75 
10 TE+Q sol 10 11,326 30/30/5/5 8 hours at 30C 2 41 9.44 0.14 67.43 
10 TE+Q sol 10 11,326 30/30/5/5 16 hours at 30C 3 60 13.94 0.21 66.38 
10 TE+Q sol 10 11,326 30/30/5/5 8 hours at 35C 3 28 10.72 0.1 107.20 
10 TE+Q sol 10 11,326 30/30/5/5 16 hours at 35C 4 49 15.13 0.17 89.00 
* total EBV genomes 20 uL of input for sWGA 713 
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Age at collection, 
N (%) 
<6 (yrs) 16 (27.6) 39 (97.5) 
7 - 13 (yrs) 42 (72.4) 1 (2.5) 
Sex, N (%) Female/Male 15/43 (25.9/74.1) 20/20 (50.0/50.0) 
Obtained 
Specimen, N (%) 
Tumor biopsy 41 (41.8) - 
Blood - 40 (100.0) 
Plasma 14 (14.2) - 
New cultured eBL 3 (3.0) - 
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No amplification Jijoye Jiyoye Assembly* 1 134,118 7.46E-06 
1.13E-05 
No amplification Daudi Daudi Assembly* 0 132,780 0.00E+00 
No amplification Raji_Rep1 Raji Assembly* 0 130,560 0.00E+00 
No amplification Raji_Rep2 Raji Assembly* 5 132,736 3.77E-05 





















eBLtumor-05_EBV_type1# 5 141,643 3.53E-05 
mlrPCR-sWGA Raji_Rep1_mlrPCR-sWGA Raji Assembly* 6 98,507 6.09E-05 
1.09E-04 
mlrPCR-sWGA Raji_Rep2_mlrPCR-sWGA Raji Assembly* 11 130,538 8.43E-05 
mlrPCR-sWGA Jijoye_Rep1_mlrPCR-sWGA Jiyoye Assembly* 13 132,045 9.84E-05 
mlrPCR-sWGA Daudi_mlrPCR-sWGA Daudi Assembly* 25 130,160 1.92E-04 
*Reference assemblies from Palser et al. 2015 (Jijoye: LN827800, Daudi: LN827545, Raji: KF717093). #The isolates were 719 
sequenced without any amplification. Preprocess denotes whether sample DNA was amplified prior to sequencing library 720 
preparation. The number of substitutions were determined by pairwise whole genome alignments of control and reference 721 
assemblies. Error rates were referred to the average mismatches to reference assemblies after normalizing to total covered genomic 722 
regions. GenomiPhi-WGA; whole genome amplification using EBV specific protected hexamers, mlrPCR-sWGA; pre-amplification 723 
with PCR primer pools followed by sWGA. 724 
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Table 4. Characteristics of children included in our study and viral genome subtypes. 727 
 728 






1 7.57 14 14 
2 4 2 2 
Male 
1 6.81 27 28 
2 7.08 26 27 




1 3.36 7 7 
2 3.58 26 27 
Male 
1 3.3 12 12 
2 3.74 16 16 
EBV subtypes are represented as 1, 2 and 1/2 for inter-typic. 729 
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Table 5. Single nucleotide variants associated with eBL. 732 
Gene Position Ref Alt 
AA 
Change 








EBNA2 37668 T C S485P 54 24 36 2 0.000328 0.1 
EBNA1 95773 A T N38Y 57 3 36 11 0.001322 6.67213 
EBNA1 95778 T G H39Q 57 3 37 12 0.000538 7.16129 
BcLF1 124703 T G K159T 56 1 34 7 0.003178 12.7377 
BcLF1 124709 G A A157V 56 1 34 7 0.003092 12.7377 
BARF1 165131 T C V29A 57 36 36 10 0.004082 0.349462 
Single nucleotide variant association test results with P < 0.01 after type stratification. Table 733 
summarizes the statistically significant single nucleotide variant associations and their effects in the 734 
coding regions. Reference is the genotype based on the consensus of all genomes in the sequencing 735 
set and variant position denotes the projection to type 1 reference genome (NC_007605). The 736 
association test has been performed for every variant position comparing the frequency of reference 737 
and alternative (minor allele) bases among eBL patient and healthy control children (Fisher’s exact 738 
test). Empirical p values were based on one million permutations. *Genomes with missing data (Ns, 739 
lack of coverage) were excluded. Ref: reference allele, Alt: alternative/variant allele, AA: amino acid, P: 740 
p-value, OR: odds ratio.  741 
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Figure Legends 743 
Figure 1. Optimized EBV genome sequencing from tumors and primary clinical samples. 744 
A) Optimization results of various dNTP concentrations in mlrPCR-sWGA reaction measured as EBV 745 
copy increase normalized by overall DNA increase. B) Incubation buffer (TE: Tris-EDTA, or Q 746 
solution), time (8 or 16 hours), and temperature optimization for better EBV copy increase. C) 747 
Overview of sample collection and methods for sequencing virus from Kenyan children diagnosed 748 
with eBL and healthy children as controls. Hybrid capture was universally performed along with 749 
additional amplification and enrichment steps to overcome low amounts of virus and input DNA. 750 
mlrPCR-sWGA; multiplexed long range PCR - specific whole genome amplification.  751 
 752 
Figure 2. Sequencing and detection quality, plasma-tumor pairs, and atypical genome isolates. 753 
A) Controls for putative mixed infections and sampling bias against EBV types. The sensitivity of EBV 754 
genome typing approach measured by accurate type assignments of in-lab mixtures with predefined 755 
ratios. Each mixture of Daudi (type 1) and Jijoye (type 2) with varying ratios was prepared in 756 
replicates. Following the genome assembly, type of the major strain was determined as judged by the 757 
distance to both reference viral genomes. B) Comparison of viral load levels of individuals carrying 758 
different EBV types (P=0.529, t-test). The non-significant difference suggests unbiased sampling 759 
among either type regardless of viral loads. We quantified viral loads with bi-plex qPCR using primers 760 
for viral BALF5 and human beta-actin gene. C) Comparison of virus from paired tumor (filled pink 761 
circles) and plasma samples (hollow pink circles) at diagnosis shows viral DNA circulating in the 762 
peripheral blood represents the virus in the tumor. The Neighbor-Joining tree is scaled (0.001 763 
substitutions per site) and includes standard reference genomes for type 1 (NC007605, blue 764 
diamond) and type 2 (NC009334, red diamond). D) The depth of coverage showing an absence of 765 
reads from approximately 100 kb to 120 kb is indicative of a large deletion in the virus from an eBL 766 
tumor (top panel). In the middle and lower panels, although we did not detect any in our tumor or 767 
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control viruses, we detected the deletions previously described in tumor lines including EBNA3C 768 
deletion in Raji and EBNA2 deletion in Daudi strains. E) Three intertypic viruses were detected by 769 
scanning across the genomes for percent identity in 1kb windows to both type 1 and type 2 770 
references (NC_007605, NC_009334, respectively). Top two graphs (grey) represent controls, Jijoye 771 
and Namalwa, followed by 3 intertypic viruses from this study and one publicly available intertypic 772 
virus (LN827563.2_sLCL-1.18 in grey).  773 
Figure 3. Diversity and phylogenetic analysis of EBV genomes in Kenyan population. 774 
A) Phylogenetic tree of the western Kenya EBV genomes demonstrating the major type 1 and type 2 775 
demarcation (blue and red branches, respectively). Pairwise distance calculations were based on 776 
Jukes-Cantor nucleotide substitution model, and the tree was constructed with the simple Neighbor-777 
Joining method. Genomes are colored based on sample type: healthy children blood (green squares), 778 
eBL tumors (full pink circles), plasma of eBL children (hollow pink circles), and new and previous cell 779 
lines (pink and yellow triangles, respectively). Low coverage genomes are excluded. B) Principal 780 
coordinates analysis plots of nucleotide variations among whole genome sequences with first and 781 
second axes (upper plot, colored by sample type), and second and third axes (lower plot, colored by 782 
EBV subtype and shapes represent case and control), which separates type 2 genomes into groups 783 
A and B (dashed red ellipses). Color coding is the same as in A. C) First and second axises of PCoA 784 
using only type 2 genomes showing the separation of two groups. D) Absolute loading values of Axis 785 
1 from PCoA with all variants are plotted throughout the genome. Values are averaged across 1 kb 786 
window. Dashed arrow marks the region for sequence variations that predominantly drives the 787 





























Figure 4. Diversity in EBV coding genes, significant associations of EBV type 1 genomes 792 
and single nucleotide variants with eBL. 793 
A) Genetic distance metrics of each EBV gene calculated based on the Kimura-2-parameter 794 
method averaged across all genomes (upper panel) or type 1 / type 2 separately (middle panel). 795 
Lower panel shows nonsynonymous to synonymous change (dN/dS) ratios of viral protein 796 
coding genes averaged across all pairwise comparisons within each group separately. Error 797 
bars represent standard error of mean. (Three intertypic genomes are excluded). B) Average 798 
synonymous and non-synonymous variants in genes are summarized as functional categories 799 
of genes. Variant level represents the number of variants per gene normalized by gene length in 800 
kb. C) The frequency of type 1 and type 2 genomes identified from eBL patients and healthy 801 
control children (excluding the three intertypic hybrid genomes is significantly different (P=0.007, 802 
Fisher’s exact). D) Manhattan plot for genome-wide associations of all single nucleotide variants 803 
tested for frequency differences between cases and controls controlling for type specific 804 
variants. The significance of each locus association is represented with an empirical p-value 805 
(negative log10 scale) that was calculated by 1 million permutations with random label 806 
swapping. Permutations were stratified for EBV genome type and adjusted for the missing 807 
genotypes due to lack of coverage. All significant variants associated with eBL cases are shown 808 
in red (P < 0.01). Nucleotide positions are according to type 1 reference genome. 809 
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